Journal
BLOOD
Volume 131, Issue 17, Pages 1931-1941Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2017-07-797209
Keywords
-
Categories
Funding
- Korean Healthcare Technology R&D project through the Korean Health Industry Development Institute - Ministry of Health & Welfare, Republic of Korea [HI13C2148, HI16C2387]
- International Research & Development Program of the National Research Foundation of Korea - Ministry of Science, ICT and Future Planning [2015K1A4A3047851]
- National Research Foundation of Korea - Korea government [2017R1C1B2002183]
- National Cancer Institute of the National Institutes of Health [P30CA034196]
- Ewha Womans University
- NATIONAL CANCER INSTITUTE [U24CA224067, P30CA034196] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas (EBV1-DLBLs) tend to occur in immunocompromised patients, such as the elderly or those undergoing solid organ transplantation. The pathogenesis and genomic characteristics of EBV1-DLBLs are largely unknown because of the limited availability of human samples and lack of experimental animal models. We observed the development of 25 human EBV1-DLBLs during the engraftment of gastric adenocarcinomas into immunodeficient mice. An integrated genomic analysis of the human-derived EBV1-DLBLs revealed enrichment ofmutations in Rho pathway genes, including RHPN2, and Rho pathway transcriptomic activation. Targeting the Rho pathway using a Rho-associated protein kinase (ROCK) inhibitor, fasudil, markedly decreased tumorgrowth inEBV1-DLBL patient-derived xenograft (PDX) models. Thus, alterations in the Rho pathway appear to contribute to EBV-induced lymphomagenesis in immunosuppressed environments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available